Whilst GLP-1 medications effectively promote weight reduction, working with healthcare professionals to achieve a steady, controlled rate of loss may allow skin greater opportunity to adapt
In the semaglutide group, 569 out of 8803 patients (6.5%) experienced a primary cardiovascular end-point event, compared to 701 out of 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80
This type of DNA damage is more evident in MDA-MB-231 or BT-549 breast cancer cells, manifesting at replication forks and causing replication stress [196]
Semaglutide often causes nausea or vomiting, especially when first starting the medication or after increasing the dose
Menopause makes blood sugar harder to manage, with spikes, crashes, and rising insulin resistance as estrogen falls